Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: J Nucl Med. 2013 Dec 12;55(1):23–29. doi: 10.2967/jnumed.113.122630

FIGURE 2.

FIGURE 2

Visualization of bone and nodal metastases. Shown are transaxial PET-CT fusion images of (A) 18F-FDG, (B) 64Cu-DOTA-trastuzumab 23 h post injection and (C) 64Cu-DOTA-trastuzumab 48 h post injection from a patient given 50 mg of trastuzumab. Upper intensity thresholds (white color) correspond to SUV = 10 g/ml. Lesion to non-lesion contrast improved modestly between Day 1 and Day 2 after 64Cu-DOTA-trastuzumab injection. A lesion growing out of the left first rib (white arrows) is well visualized on the Day 1 64Cu scan and little changed on Day 2. A spinal metastasis (turquoise arrows) not seen with 18F-FDG is well visualized on both the Day 1 and Day 2 64Cu scans. On the other hand, a nodal metastasis (red arrows) seen with 18F-FDG is visualized only on Day 2 with 64Cu-DOTA-trastuzumab.